Deflazacort
- TRADE NAME: Emflaza (Marathon)
- INDICATIONS: Duchenne muscular dystrophy
- CLASS: Corticosteroid / Glucocorticoid
- HALF-LIFE: N/A
FDA APPROVAL DATE: 02/09/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Carbamazepine, Clarithromycin, Diltiazem, Efavirenz, Fluconazole, Grapefruit Juice, Live vaccines, Pancuronium, Phenytoin, Rifampin, Verapamil
PREGNANCY CATEGORY: N/A
Should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.
Page last updated 02/12/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric